GSK GSK plc

   By Oliver Griffin 
 

GlaxoSmithKline PLC (GSK.LN) Friday said its majority-owned ViiV Healthcare has received a positive opinion from European medical authorities for its Dovato HIV treatment.

The pharmaceutical company said that ViiV--which also counts Pfizer Inc. (PFE) and Shionogi & Co. Ltd. (4507.TO) as shareholders--received a positive opinion from the Committee for Medicinal Products for Human Use, recommending marketing authorization for Dovato.

The committee, which is part of the European Medicines Agency, issued the opinion based on landmark studies, GlaxoSmithKline said.

Dovato is for the treatment of HIV-1 infection in adults and adolescents above 12 years of age, the company said.

An opinion from the Committee for Medicinal Products for Human Use is one of the final steps before a marketing authorization decision is made by the European Commission, the company said.

Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin

(END) Dow Jones Newswires

April 26, 2019 11:45 ET (15:45 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.